Skip to main content
JETEMA Co.,Ltd. logo

JETEMA Co.,Ltd. — Investor Relations & Filings

Ticker · 216080 ISIN · KR7216080002 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2024-04-04 Major Shareholding Noti…
Country KR South Korea
Listing KO 216080

About JETEMA Co.,Ltd.

http://www.jetema.com/

JETEMA Co., Ltd. is a research-driven biopharmaceutical company specializing in the development and manufacturing of innovative medicines and medical devices for the aesthetic medicine market. The company's core product portfolio includes botulinum toxins, hyaluronic acid-based dermal fillers, and lifting threads. With a strong focus on research and development, JETEMA aims to provide advanced solutions for anti-aging and aesthetic enhancement. The company's name is derived from the Latin word 'Zetéma', meaning 'research', reflecting its commitment to scientific innovation in creating products for a healthy and beautiful life.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings, and major contracts (such as stock collateral agreements) of the company's largest shareholder and their special related parties. This type of document is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-04-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by a director (Nam Jeong-sun) of Jetema Co., Ltd. This type of filing is a standard regulatory requirement for reporting insider transactions or changes in share ownership by company directors/executives. According to the provided definitions, this falls under 'Director's Dealing' (DIRS).
2024-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director appointments, and remuneration limits. This matches the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at general meetings.
2024-03-25 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (제테마더톡신주 100단위 (JTM201)의 중국 임상 2상면제 및 3상개시 신청 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the approval of a Phase 3 clinical trial for a pharmaceutical product (JTM201) in China. Since this is a formal regulatory disclosure of a material business event (clinical trial status) and does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2024-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial statements, audit opinions, and key financial metrics (assets, liabilities, revenue, profit) for the current and previous fiscal years. While it contains financial data, it is a standard regulatory disclosure form used to announce the completion and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-15 Korean
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) and covers the fiscal period from January 1, 2023, to December 31, 2023. It contains comprehensive company information, including management details, business overview, financial data, and governance information. In the context of Korean corporate filings, '사업보고서' is the standard annual report required by the Financial Supervisory Service, which corresponds to the 10-K filing type in the provided schema. FY 2023
2024-03-15 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.